The 100-Year Life Health Education and Government
US obesity levels have dropped for the first time on record and Ozempic may be behind it. This would be the inference from US public health agency data: the obesity rate has fallen fastest among college graduates, the group considered most likely to use expensive weight-loss drugs. One in eight US adults have now used Ozempic, which could turn out to be a generational game changer in the health of the developed world (although there is currently a global shortage of the drug). Ozempic also appears to have halted the rise in obesity in Denmark, the home of the drug’s creator Novo Nordisk. But some are uneasy. The Danish healthcare industry is under fire for accepting training courses funded by Novo. Some opposition MPs say that is a conflict of interest; certainly it reflects the company’s national power. Last year nearly one out of every five Danish jobs created was at Novo, and this year analysts predict the company’s success will account for half of Denmark’s GDP growth.
